Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial

The Lancet Infectious Diseases

Volumn 21, Issue 11, 2021, Pages 1579-1589

  McLean, Alistair R D ^a,b,c   Indrasuta, Chanida ^a   Khant, Zay Soe ^a   Phyo, Aung Kyaw ^a   Maung, Sai Maung ^a   Heaton, James ^a   Aung, Hein ^a   Aung, Ye ^a   Soe, Kyaw ^b   Swe, Myo Maung Maung ^b   von Seidlein, Lorenz ^d   Tun, Ni Ni ^a,b   Tun, Kyaw Myo ^e   Day, Nicholas P J ^c,d   Ashley, Elizabeth A ^b,c   Hlaing, Thaung ^f   Kyaw, Thar Tun ^f   Dondorp, Arjen M ^c,d   Imwong, Mallika ^c,d   White, Nicholas J ^c,d   Smithuis, Frank M ^a,b,c   more..

^a Medical Action Myanmar   (Myanmar)

^b Myanmar   (Myanmar)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d MAHIDOL UNIVERSITY   (Thailand)

^e Defence Services Medical Academy   (Myanmar)

^f Ministry of Health and Sports   (Myanmar)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMISININ; DIHYDROARTEMISININ PLUS PIPERAQUINE; PRIMAQUINE; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; DIHYDROARTEMISININ; PIPERAQUINE; QUINOLINE DERIVATIVE;

ADOLESCENT; ADULT; ADVERSE EVENT; ARTICLE; CASE MANAGEMENT; CHILD; CLUSTER ANALYSIS; CONTACT EXAMINATION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEALTH AUXILIARY; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALARIA; MALARIA CONTROL; MALARIA FALCIPARUM; MALE; MASS DRUG ADMINISTRATION; MYANMAR; OUTCOME ASSESSMENT; PARASITEMIA; PREVALENCE; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; REAL TIME POLYMERASE CHAIN REACTION; RURAL POPULATION; SEASONAL VARIATION; SINGLE DRUG DOSE; TREATMENT OUTCOME; URINE COLOR; COMBINATION DRUG THERAPY; DISEASE ERADICATION; DRUG RESISTANCE; PARASITOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIMALARIALS; ARTEMISININS; CHILD; CLUSTER ANALYSIS; DISEASE ERADICATION; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALARIA, FALCIPARUM; MALE; MASS DRUG ADMINISTRATION; MYANMAR; PRIMAQUINE; QUINOLINES; YOUNG ADULT;

EID: 85116198986     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(20)30997-X     Document Type: Article

References (30)

1. WHO. World malaria report 2016. https://www.who.int/malaria/publications/world-malaria-report-2016/report/en, 2016. (Accessed 23 August 2018)
2. Ashley, EA, Dhorda, M, Fairhurst, RM, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 371 (2014), 411–423.
3. Tun, KM, Jeeyapant, A, Imwong, M, et al. Parasite clearance rates in Upper Myanmar indicate a distinctive artemisinin resistance phenotype: a therapeutic efficacy study. Malar J, 15, 2016, 185.
4. Amaratunga, C, Lim, P, Suon, S, et al. Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study. Lancet Infect Dis 16 (2016), 357–365.
5. Phyo, AP, Ashley, EA, Anderson, TJC, et al. Declining efficacy of artemisinin combination therapy against P. falciparum malaria on the Thai-Myanmar Border (2003–2013): the role of parasite genetic factors. Clin Infect Dis 63 (2016), 784–791.
6. Tun, KM, Imwong, M, Lwin, KM, et al. Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker. Lancet Infect Dis 15 (2015), 415–421.
7. Imwong, M, Suwannasin, K, Kunasol, C, et al. The spread of artemisinin-resistant Plasmodium falciparum in the Greater Mekong subregion: a molecular epidemiology observational study. Lancet Infect Dis 17 (2017), 491–497.
8. Imwong, M, Dhorda, M, Myo Tun, K, et al. Molecular epidemiology of resistance to antimalarial drugs in the Greater Mekong subregion: an observational study. Lancet Infect Dis 20 (2020), 1470–1480.
9. Tun, KM, Jeeyapant, A, Myint, AH, et al. Effectiveness and safety of 3 and 5 day courses of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in an area of emerging artemisinin resistance in Myanmar. Malar J, 17, 2018, 258.
10. Wellems, TE, Hayton, K, Fairhurst, RM, The impact of malaria parasitism: from corpuscles to communities. J Clin Invest 119 (2009), 2496–2505.
11. McLean, ARD, Wai, HP, Thu, AM, et al. Malaria elimination in remote communities requires integration of malaria control activities into general health care: an observational study and interrupted time series analysis in Myanmar. BMC Med, 16, 2018, 183.
12. Imwong, M, Hanchana, S, Malleret, B, et al. High-throughput ultrasensitive molecular techniques for quantifying low-density malaria parasitemias. J Clin Microbiol 52 (2014), 3303–3309.
13. Imwong, M, Stepniewska, K, Tripura, R, et al. Numerical distributions of parasite densities during asymptomatic malaria. J Infect Dis 213 (2016), 1322–1329.
14. Nguyen, TN, von Seidlein, L, Nguyen, TV, et al. The persistence and oscillations of submicroscopic Plasmodium falciparum and Plasmodium vivax infections over time in Vietnam: an open cohort study. Lancet Infect Dis 18 (2018), 565–572.
15. Poirot, E, Skarbinski, J, Sinclair, D, Kachur, SP, Slutsker, L, Hwang, J, Mass drug administration for malaria. Cochrane Database Syst Rev, 12, 2013, CD008846.
16. White, NJ, Does antimalarial mass drug administration increase or decrease the risk of resistance?. Lancet Infect Dis 17 (2017), e15–e20.
17. Gutman, J, Kovacs, S, Dorsey, G, Stergachis, A, Ter Kuile, FO, Safety, tolerability, and efficacy of repeated doses of dihydroartemisinin-piperaquine for prevention and treatment of malaria: a systematic review and meta-analysis. Lancet Infect Dis 17 (2017), 184–193.
18. Sahan, K, Pell, C, Smithuis, F, et al. Community engagement and the social context of targeted malaria treatment: a qualitative study in Kayin (Karen) State, Myanmar. Malar J, 16, 2017, 75.
19. Imwong, M, Hien, TT, Thuy-Nhien, NT, Dondorp, AM, White, NJ, Spread of a single multidrug resistant malaria parasite lineage (PfPailin) to Vietnam. Lancet Infect Dis 17 (2017), 1022–1023.
20. Donner, A, Donald, A, Analysis of data arising from a stratified design with the cluster as unit of randomization. Stat Med 6 (1987), 43–52.
21. WHO. Status report on artemisinin resistance and ACT efficacy. https://www.who.int/malaria/publications/atoz/artemisinin-resistance-august2018/en, August, 2018. (Accessed 25 September 2018)
22. Smithuis, F, Kyaw, MK, Phe, O, et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial. Lancet Infect Dis 10 (2010), 673–681.
23. Landier, J, Kajeechiwa, L, Thwin, MM, et al. Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant falciparum malaria: a pilot trial in four villages of eastern Myanmar. Wellcome Open Res, 2, 2017, 81.
24. Landier, J, Parker, DM, Thu, AM, et al. Effect of generalised access to early diagnosis and treatment and targeted mass drug administration on Plasmodium falciparum malaria in eastern Myanmar: an observational study of a regional elimination programme. Lancet 391 (2018), 1916–1926.
25. Hamainza, B, Moonga, H, Sikaala, CH, et al. Monitoring, characterization and control of chronic, symptomatic malaria infections in rural Zambia through monthly household visits by paid community health workers. Malar J, 13, 2014, 128.
26. Delacollette, C, Van der Stuyft, P, Molima, K, Using community health workers for malaria control: experience in Zaire. Bull World Health Organ 74 (1996), 423–430.
27. Adhikari, B, James, N, Newby, G, et al. Community engagement and population coverage in mass anti-malarial administrations: a systematic literature review. Malar J, 15, 2016, 523.
28. von Seidlein, L, Peto, TJ, Landier, J, et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in Southeast Asia: a cluster randomised trial. PLoS Med, 16, 2019, e1002745.
29. Kaneko, A, Taleo, G, Kalkoa, M, Yamar, S, Kobayakawa, T, Björkman, A, Malaria eradication on islands. Lancet 356 (2000), 1560–1564.
30. Deng, C, Huang, B, Wang, Q, et al. Large-scale artemisinin-piperaquine mass drug administration with or without primaquine dramatically reduces malaria in a highly endemic region of Africa. Clin Infect Dis 67 (2018), 1670–1676.